Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Commission Consults On New Risk-Proportionate Approaches Under EU Clinical Trials Regulation

This article was originally published in SRA

Executive Summary

The European Commission is inviting stakeholder feedback on recommendations to help implement several key aspects of the new EU Clinical Trials Regulation, including how to apply a risk proportionate approach for the design and conduct of trials, and how to present a summary of clinical trial results to laypersons1.


Related Content

Industry Sees Little Benefit Of New EU Clinical Trial Rules On Information Materials For Minors
Pharma Wants More Clarity On Use Of Auxiliary Products In EU Trials
Pharma Requests Pilot To Test Public Value Of EU Guide On Plain Language Summaries
Pharma Calls For Practical Advice On Using Risk-Based Approach To Trials in EU
Redacting Personal Data/CCI In EU Clinical Trial Inspection Reports On The Agenda



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts